In focus · trending topic

ORPHAN DRUGS

30 stories · following the connections

ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology

By Nasdaq OMXSep 21, 2017, 11:05 AM UTC

ProQR to Present at Two Investor Conferences in September

By Nasdaq OMXSep 21, 2017, 11:00 AM UTC

ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

By Nasdaq OMXSep 19, 2017, 11:01 AM UTC

ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics

By Nasdaq OMXSep 12, 2017, 11:00 AM UTC

ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

By Nasdaq OMXSep 5, 2017, 11:01 AM UTC

ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong

By Nasdaq OMXAug 28, 2017, 11:00 AM UTC

ProQR Announces Results for the Second Quarter of 2017

By Nasdaq OMXAug 16, 2017, 11:00 AM UTC

ProQR Announces R&D Day in New York on June 15

By Nasdaq OMXMay 9, 2017, 11:02 AM UTC